These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3266542)

  • 1. Serum osteocalcin concentration in patients with prostatic cancer.
    Francini G; Bigazzi S; Leone V; Gennari C
    Am J Clin Oncol; 1988; 11 Suppl 2():S83-7. PubMed ID: 3266542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism.
    Stĕpán JJ; Presl J; Broulík P; Pacovský V
    J Clin Endocrinol Metab; 1987 May; 64(5):1079-82. PubMed ID: 3031119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serum osteocalcin as an index of altered bone metabolism.
    Kruse K; Kracht U
    Eur J Pediatr; 1986 Apr; 145(1-2):27-33. PubMed ID: 3015628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
    Marcellini M; De Carli P; Abbolito MR; Mainiero G; Cantiani R
    Eur Urol; 1992; 21 Suppl 1():102-4. PubMed ID: 1385126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
    Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
    Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
    Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
    Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
    Bishop MC; Fellows GJ
    Br J Urol; 1977; 49(7):711-6. PubMed ID: 597712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB; Jeannet C; Depierre D; Courvoisier B
    Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical markers and skeletal metabolism in carcinoma of the prostate. Use of decision matrix theory and ROC analysis.
    Urwin GH; Percival RC; Yates AJ; Watson ME; Couch M; McDonald B; Forrest AR; Williams JL; Kanis JA
    Br J Urol; 1985 Dec; 57(6):711-4. PubMed ID: 3002534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
    Francini G; Montagnani M; Petrioli R; Paffetti P; Marsili S; Leone V
    Int J Biol Markers; 1990; 5(2):65-72. PubMed ID: 2283479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
    Nemoto S; Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
    [No Abstract]   [Full Text] [Related]  

  • 13. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
    Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
    J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone imaging and serum phosphatases in prostatic carcinoma.
    Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
    Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
    Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K; Aoyagi K
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blood levels of osteocalcin in hemodialysis patients. Significance and relations with uremic osteodystrophy].
    Bongiorno P; Biamino E; Caligaris F; Imarisio P; Montalcini G; Gentile G; Elia M; Arnaud A
    Minerva Urol Nefrol; 1988; 40(4):323-6. PubMed ID: 3266950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.